BBlogFlow

Navigating oligometastatic breast cancer: the role of stereotactic radiotherapy - Oncology Central

·48m ago
Source: Oncology Central
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

In this interview, Imogen Locke (The Royal Marsden NHS Foundation Trust, UK) discusses the evolving role of stereotactic ablative radiotherapy (SABR) in oligometastatic and oligoprogressive breast cancer.

Locke explains the distinction between these two clinical scenarios, how timing and patient selection influence treatment decisions, and emerging evidence around metastasis-directed radiotherapy for ER-positive, HER2-negative patients on CDK4/6 inhibitors. Additionally, Locke walks us through a patient case study and highlights key radiotherapy trials seeking to answer the most pressing questions in breast cancer radiotherapy.

This article is an excerpt. To read the full content, visit the original source. Oncology Central

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Multimodal AI refines EAU risk stratification in patients undergoing radiotherapy for prostate cancer - Nature

IntroductionRisk stratification before definitive treatment is fundamental to prostate cancer management, guiding treatment intensity and patient counseling. The European Association of Urology (EAU) risk classification system, based on prostate-specific antigen (PSA), International Society of Urological Pathology (ISUP) grade group, and clinical stage, remains the cornerstone for treatment decision-making in patients undergoing radiotherapy (RT)1. Despite their clinical utility, outcome heterogeneity remains substantial. In a Swedish population-based cohort of patients treated with RT, the 15-year cumulative incidence of biochemical recurrence (BCR) ranged from 18% in EAU low-risk disease to 36% in EAU high-risk disease, indicating that currently used categories do not fully capture individual prognosis2. Improving pre-treatment prognostic stratification may therefore help identify clinically distinct subgroups within established categories.

Nature·

Measles outbreak in Bangladesh is a ‘real warning’ to other nations, experts say - NBC News

But that same year, protests erupted that ended 15 years of rule by Prime Minister Sheikh Hasina. In the ensuing political turmoil, health workers went on strike, vaccine orders were delayed and follow-up vaccinations that usually accompany routine programs were disrupted. In a report published in July this year, WHO and UNICEF estimated that first-dose coverage in 2025 had fallen to 90%, while second-dose coverage was 86%, several percentage points below the 95% needed for herd immunity. The report also raised questions about the quality of official data on vaccinations for measles and other diseases for the years 2023 to 2025. It said preliminary figures sometimes showed numbers of those inoculated exceeded 100% of those targeted, indicating mistakes in counting doses or target numbers. Emergency program missed millionsStill, when the measles outbreak erupted, Bangladesh responded swiftly and initially seemed to be winning the battle. An emergency program was followed by an initial slowdown in new cases after almost 20 million children received vaccinations in April and May. The government said it had covered every child in the target age group of 6 months to 5 years.

NBC News·

Equatorial Guinea is expanding an ambitious malaria elimination plan - Medical Xpress

Health workers prepare to visit communities to spray insecticide and help prevent the spread of malaria in Malabo, Equatorial Guinea, April 24, 2026. Credit: AP Photo/Misper Apawu With its torrential rains, tropical forests and omnipresent humidity, Equatorial Guinea provides the perfect conditions for mosquitoes to breed. For centuries, mosquito-borne diseases, in particular malaria, have dictated the fate of residents of this central African nation, impacting how they lived, worked and died.

Medical Xpress·